Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Date:11/5/2007

Data presented at the 13th Annual Meeting of Connective Tissue Oncology Society held in Seattle, Washington demonstrates clinical activity and

tolerability of perifosine as a single agent in patients with

chemo-insensitive sarcomas

NEW YORK, Nov. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that preliminary data demonstrating the tolerability and clinical activity of KRX-0401 (perifosine) in patients with refractory, rare sarcomas was presented on Saturday, November 3, 2007 at the Annual Meeting of the Connective Tissue Oncology Society.

In an oral presentation entitled "A PHASE II TRIAL OF PERIFOSINE IN PATIENTS WITH CHEMO-INSENSITIVE SARCOMAS: PRELIMINARY RESULTS," Dr. Joseph Ludwig Assistant Professor, Dept of Sarcoma, MD Anderson Cancer Center reported on preliminary Phase 2 data in which single agent perifosine demonstrated a 40% overall clinical benefit (Stable Disease > 3 months) in these subsets of patients. Assessment of response was completed by both, RECIST and Choi criteria, and results by sarcoma subtype as follows:

Sarcoma Histology Evaluable PR (Choi) SD > 12 wks

Patients N (%) N (%)

Chondrosarcoma 25 1 (4%) 5 (20%)

Extra-Skeletal Myxoid 13 2 (15%) 5 (38%)

Alveolar Soft Part 10 3 (30%) 3 (30%)

TOTAL 48 6 (13%) 13 (27%)

Perifosine was also well tolerated with the most common grade 1 & 2 adverse events reported as nausea, vomiting, diarrhea and fatigue.

C
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... DUBLIN , June 02, 2015 Research ... of the "Europe Fluoroscopy Market - Growth, Trends ... offering. The European market for Fluoroscopy is ... to 2020 Fluoroscopy is used to view ... catheter through blood vessels, bile ducts or the urinary ...
(Date:6/2/2015)... , June 02, 2015 Research and Markets( ... Mammography Market - Growth, Trends And Forecasts (2014 - 2019)" ... market is dominated by the Germany . ... . Developing nations such as Poland ... for mammography equipment can be segmented on the basis of ...
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/w3n5p6/drug_delivery_in ) has ... "Drug Delivery in Central Nervous System Diseases ... offering. The delivery of drugs to ... the treatment of neurological disorders. Drugs may be ... (e.g., by intravenous injection) for targeted action in ...
Breaking Medicine Technology:European Fluoroscopy Market Report 2014-2019 - Growth, Trends And Forecasts 2Europe Mammography Market Report 2014-2019 - Growth, Trends And Forecasts 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 2Global Drug Delivery in Central Nervous System Diseases Report 2015-2024 - Technologies, Markets and Companies 3
... , WALTHAM, Mass., Dec. 9 Decision Resources, one ... pharmaceutical and healthcare issues, finds that compared to last year,s ... used more often to treat newly diagnosed patients suffering from ... received a TNF-alpha inhibitor versus one year ago (15.2 percent ...
... , NEW ... research report is available in its catalogue: , Medical ... http://www.reportlinker.com/p0164322/Medical-Fiber-Optics---A-World-Market-Analysis.html , Fiber optics work on the principle ... an element encased by glass in air of low refractive ...
Cached Medicine Technology:TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 2Reportlinker Adds Medical Fiber Optics - A World Market Analysis 3Reportlinker Adds Medical Fiber Optics - A World Market Analysis 4Reportlinker Adds Medical Fiber Optics - A World Market Analysis 5Reportlinker Adds Medical Fiber Optics - A World Market Analysis 6
(Date:6/2/2015)... Milton Hershey School® graduate Vincent Klomps ’10 ... of the Physician Assistant Program’s entering class of 2015 ... with a white coat, which symbolizes his entrance into ... of Vincent’s accomplishments both at MHS and postgraduation,” said ... of how a top-notch education can lead to achievement ...
(Date:6/2/2015)... MI (PRWEB) June 02, 2015 Erbelli’s ... new website to promote its handmade gourmet pizzas and ... even though the website is new, the recipes are ... since 1995. The main feature of the site is ... appetizing pictures and descriptions of all the items. You ...
(Date:6/2/2015)... June 02, 2015 IMPAK Corporation, ... systems, has announced the availability of “child-resistant” pouches ... poisons by children, especially curious toddlers. The Child ... and tested to CFR 1700.20 protocols. The announcement ... , Looks Like Candy, “With the proliferation of ...
(Date:6/2/2015)... Acara Partners has seen a spike in ... mobile devices, as is now required by recent Google search ... well as several new clients in the medical aesthetics vertical, ... them to meet Google’s new requirements,” commented Fran Acunzo, CEO ... clients in education, non-profits, and the business world.” , ...
(Date:6/2/2015)... DiaTech Oncology, provider of CorrectChemo®, ... to help oncologists provide personalized cancer treatment, has ... (CAP) for its laboratories in the U.S. and ... to the ‘Good Housekeeping’ seal of approval,” says ... for DiaTech. “It’s a rigorous inspection that confirms ...
Breaking Medicine News(10 mins):Health News:Erbelli’s of Bradenton Launches New Mobile-Friendly Website 2Health News:IMPAK Introduces Child Resistant Zip Pouches & Bags 2Health News:Acara Partners Expands Website and Digital Offerings 2Health News:DiaTech Oncology Gains College of American Pathologists Accreditation for U.S. CorrectChemo Laboratory 2
... BUFFALO, N.Y. -- The University at Buffalo announced today a ... and family to establish the Jacobs Institute, which will support ... of heart and vascular diseases. , ... was made in honor of Lawrence D. Jacobs, M.D., a ...
... 13 Market competition is,mounting to win ... most highly,qualified clinical investigators. Companies that develop ... their studies win an advantage in,bringing their ... white paper "Recruiting and Retaining,High-Quality Clinical Investigators" ...
... for recent disasters, WASHINGTON, June 13 The ... with relief efforts for,the victims of flooding and tornadoes ... West Virginia, the Red Cross is present,with vast amounts ... of,thousands of meals., Already, more than 1,400 Red ...
... Long and costly product,development cycles make it essential ... to the development of compounds with,the greatest potential ... and earlier into the new product process in ... development cycle,time, focus resources for greatest impact and ...
... lead to diagnostic urine test for 10% of men with ... traits of an aggressive type of prostate cancer that occurs ... been identified in hopes of finding a way to diagnose ... the Michigan Center for Translational Pathology at the University of ...
... June 2008: The TRAF1/C5 locus on chromosome 9 has ... diseases including type 1 diabetes and systemic lupus erythematosus ... 2008, the Annual Congress of the European League Against ... Factor-receptor associated factor 1) and C5 (complement component 5) ...
Cached Medicine News:Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 2Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 3Health News:$10 million gift will retain and recruit world-class researchers to University at Buffalo 4Health News:American Red Cross Issues Appeal for Disaster Relief Fund 2Health News:Bio-Pharma Launch Value Maximized Through New Product Commercialization Excellence 2Health News:Researchers ID Traits of Aggressive Prostate Cancer 2Health News:Specific location of the TRAF1/C5 gene associated with multiple autoimmune diseases 2
... First access to the skull by trepanation. ... performance motor at standard operating pressure: 6 ... coupling. Full manual control by a progressive ... with drilling speed of approx. 800 rpm. ...
14 cm - 5 1/2, 6.0 mm , for drill handles and hand drills....
DeMartel (Bailey) Wire Saw Guide, 33 cm - 13, flexible....
Galt Skull Trephine with adjustable centering point and detachable cross-bar handle, 19.0 mm....
Medicine Products: